MiniMed announced that the MiniMed Fit patch pump has been submitted to the FDA for review. The submission comes ahead of the company’s previous target, with MiniMed now expecting a U.S. launch in summer 2027. The tubeless pump is part of MiniMed’s broader effort to expand its automated insulin delivery (AID) portfolio as competition in the patch pump market continues to grow.

MiniMed Fit is designed to hold 300 units of insulin and is made up of two components. The semi-reusable “brain” houses the electronics and connects to a disposable piece that will be replaced with each new infusion set. Users will receive two reusable, rechargeable “brain” devices. MiniMed Fit’s design is unique compared to other patch pumps. Currently, the only tubeless pump in the U.S. is Omnipod, which holds 200 units of insulin and is fully disposable. But more are in the works from Tandem, with tubeless Tandem Mobi, and Mint from Beta Bionics—both expected next year as well.

MiniMed also announced progress on Vivera, its next-generation fully closed-loop algorithm designed for people with both type 1 and type 2 diabetes. Enrollment has completed for the U.S. pivotal trial, putting the system on track for a potential U.S. launch in the second half of 2027. Vivera is an entirely new algorithm, built to work around announced and unannounced meals. The algorithm also expands the range of glucose targets, starting as low as 90 mg/dL and increasing in increments of 10 mg/dL up to 140 mg/dL.

Which MiniMed update are you most excited for? Let us know in the comments!